TBC News

Tag: medication

  • When stress breaks you apart, Stresstabs puts you back together

    When stress breaks you apart, Stresstabs puts you back together

    A surreal image showing an arm and hand emerging from a pillow, symbolizing stress and depletion, with a woman holding a vitamin box in an inset. The background features a cozy bedroom setting.

    Overworked? Sleep-deprived? You might actually be falling apart. Stresstabs’ bold new campaign, “Ibalik ang Nawalang Ikaw,” or Bring yourself back together in English, takes the invisible toll of stress and makes it strikingly – and hilariously – visible.

    In the film, we meet Jemerlyn, a Filipino office worker whose day is so tough, long, and stressful that she’s literally whittled down to nothing but an arm and a hand. The weird visual is a relatable metaphor for the way stress depletes the body’s essential nutrients.

    The twist? After taking a pill of Stresstabs, a construction crew barges into her room — armed with the nuts and bolts representing Vitamins E and C, Iron, and Niacinamide — to rebuild her piece by piece. The result: Jemerlyn feels whole again, ready to take on the day.

    Making the invisible visible

    With 87% of Filipino workers reporting job-related stress according to a recent study by AXA, Stresstabs’ striking campaign definitely hits close to home.

    Dr. Shiro Ann Noda, Medical and Scientific Affairs Manager at Haleon, Stresstabs’ parent company, explains the science behind the campaign’s message.

    “Vitamins and minerals, along with a healthy and balanced diet as well as regular exercise, are essential for your mind and body to always perform at their best. And stress isn’t just a heavy cloud that weighs on your mind—it depletes these very nutrients your body needs,” she says. “Stresstabs is designed to help replenish the lost nutrients that stress takes away.”

    A creative shakeup in consumer health advertising

    Typical vitamin ads often lean on generic smiles, lab coats, beauty shots, and direct before-and-after imagery, but with this campaign, Stresstabs goes the other way.

    This film blends emotional storytelling with a touch of absurd humor, tapping into the lived reality of modern Filipino workers, freelancers, and side-hustlers with a tale that easily resonates with many people’s daily lives.

    “With so many Filipinos overworked and under-rested, we wanted to help them understand what stress is really doing to their bodies—and how they can fight back,” says Rein Locsin, Stresstabs Brand Manager.

    The film’s creative direction flirts with surreal visuals, making it impossible to forget – and perfect for a generation that loves content with an edge.

    “We wanted to visually capture what people already feel — that stress is breaking them. And we wanted them to know—there’s a way to rebuild,” says Dani Rodelas, Senior Digital Marketing Manager. “Who says pharma ads have to be boring?”

    Don’t let stress break you apart–take Stresstabs today. Watch the full film here.

  • 8 Things to Know About the New Alzheimer’s Maintenance Injection

    8 Things to Know About the New Alzheimer’s Maintenance Injection

    The U.S. Food and Drug Administration (FDA) has approved a new way for Alzheimer’s patients in the early stages to continue treatment.

    Leqembi® IQLIK™ (lecanemab-irmb), developed by Eisai and BioArctic, is the latest advancement offering more flexibility for patients and caregivers.

    Here’s what makes this approval a breakthrough in the fight against Alzheimer’s disease.

    1. A Fresh Option for Maintenance Dosing

    Patients who have already undergone 18 months of Leqembi IV therapy now have a choice. Instead of continuing with intravenous infusions every four weeks, they can switch to a once-weekly 360 mg subcutaneous injection using the new Leqembi IQLIK autoinjector.

    2. Launch Date is Official

    The new treatment option will be rolled out across the United States starting October 6, 2025, giving patients and doctors only a short wait before it becomes available.

    3. Designed for Early Alzheimer’s Patients

    Leqembi IQLIK is specifically indicated for people with mild cognitive impairment or mild dementia, collectively known as early-stage Alzheimer’s disease. This is the window where treatment can make the most meaningful difference in slowing progression.

    4. Convenient Home Use

    Unlike IV infusions that require clinic visits, Leqembi IQLIK’s subcutaneous autoinjector can be administered at home. This means patients and caregivers may avoid long trips to infusion centers and save valuable time.

    5. Lighter Load on Healthcare Systems

    Switching to an injection reduces the demand for infusion centers, nurse supervision, and treatment preparation. This not only benefits patients but also frees up medical resources for new patients beginning therapy.

    6. Double-Action Against Alzheimer’s

    Leqembi is unique because it tackles the disease in two ways. It targets amyloid plaque and protofibrils, both of which are linked to tau buildup—a key driver in Alzheimer’s progression. This dual approach aims to slow decline more effectively than standard treatments.

    7. Backed by Long-Term Research

    The therapy stems from BioArctic’s discovery of the Arctic mutation in Alzheimer’s disease, spearheaded by Professor Lars Lannfelt. Eisai handled clinical trials and global approval applications, while both companies are working together for commercialization in the Nordic region.

    8. A Step Toward Preserving Identity

    Because stopping treatment can cause Alzheimer’s biomarkers to rebound and progression to accelerate, the availability of maintenance dosing gives patients a longer chance to preserve memory, identity, and independence.

    Alzheimer’s remains one of the toughest medical challenges worldwide, but innovations like Leqembi IQLIK offer new hope.

    With easier access, home administration, and strong scientific backing, this injection could redefine how early-stage patients manage the disease.